ThromboGenics NV (THR.BR)
29 Jul 2016
* Receives US FDA approval for new 'already-diluted' formulation of JETREA
* Cash and investments were 96.9 million euros as of end of March 2016, vs 101.4 million euros a at end of Dec. 2015 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Says Oncurious NV and Bioinvent partner with U.S. research consortium to accelerate phase I/IIa clinical development of TB-403 Source text: http://bit.ly/251lYUL Further company coverage: (Gdynia Newsroom:)
Earnings vs. Estimates
Analyst Research Reports
ThromboGenics NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Provider : Sadif Analytics Prime
"The Economy Matters" Report for TBGNF: the economy's impact on TBGNF's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider : MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.